Tests oral MBQ-167 in people with advanced breast cancer
Tests a pill, MBQ-167, in adults with advanced breast cancer.
Plain-language title generated from the registry record
Registry title: A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
Key facts
- Where
- San Juan, Puerto RicoSee the site
- Phase
- Phase 1
Where in Puerto Rico
- FDI Clinical ResearchSan Juan, Puerto RicoNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- MBQ Pharma
- Trial code
- NCT06075810
- Record updated
- 31 August 2026
- Original description
A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable.Read full original descriptionShow less
A Phase 1 Open-Label, First-in-Human Trial of Oral MBQ-167 as Single Agent in Participants With Advanced Breast Cancer
A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable.
Inclusion: The investigator will evaluate these and other criteria to determine whether a participant can be included in this study; Histologically and/or cytologically confirmed advanced breast cancer which has progressed after treatment with approved therapies or for which there are no standard therapies available; Participants with known brain metastases may be eligible if specific conditions are met; Life expectancy ≥6 months, in the opinion of the investigator, after starting MBQ-167; Are able to swallow capsules twice daily with a meal.
Exclusion: Participants who have received any anticancer treatment within 4 weeks or any investigational agent within 28 days prior to the first dose of trial drug or who have not recovered from any acute toxicity greater than Grade 0 or 1 related to previous anticancer treatment; Participants who have received any anticancer treatment within 4 weeks or any investigational agent within 28 days prior to the first dose of trial drug or who have not recovered from any acute toxicity greater than Grade 0 or 1 related to previous anticancer treatment; Inability to take oral medication, or malabsorption syndrome or any other uncontrolled gastrointestinal condition (e.g., nausea, diarrhea, or vomiting) that might impair the bioavailability of MBQ-167; Active malignancies other than advanced breast cancer will be excluded from the study; The investigator will evaluate these and other criteria to determine whether a participant should be excluded from this study; Females who are pregnant or breastfeeding.